Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
Walter Reinisch(Medical University of Vienna), Fabio Cataldi(Pfizer (United States)), Tara McDonnell Moorehead(Clinical Solutions), Sunil Khurana, Julián Panés(Hospital Clínic de Barcelona), Gail M. Comer(Pfizer (United States)), Fei Hua(Soochow University), Karen Page(Pfizer (United States)), Gábor Tóth(Szent János Kórház), Yanhui Sun(Pfizer (China)), Huachen Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Margot O’Toole(Pfizer (United States)), Michelle Hinz(Pfizer (United States))
Cited by 157
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
|Nature Metabolism|2020|775